<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464682</url>
  </required_header>
  <id_info>
    <org_study_id>HS-25-C-01</org_study_id>
    <nct_id>NCT03464682</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia</brief_title>
  <acronym>HS-25-C-01</acronym>
  <official_title>Multi-center,Randomized,Double Blind,Double Dummy,Placebo Controlled,Efficacy and Safety Study of HS-25 in Combination With Atovastatin in Adults With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Hisun Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Hisun Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of the HS-25 (10mg or 20mg) or in combination with Atorvastatin
      (10mg)in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period
      of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25
      (10mg or 20mg) or in combination with Atorvastatin (10mg)in subjects with LDL-C after a
      40-week period of treament.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week, randomized, double-blind, double dummy, placebo-controlled study designed
      to assess the effects of the cholesterol absorption inhibitor HS-25 (10mg or 20mg) or in
      combination with Atorvastatin (10mg) on LDL-C levels in adults who have untreated LDL-C
      levels ranging from 3.36-4.88mmol/L(130-189 mg/dL)and fasting triglyceride levels &lt; 350
      mg/dL. Eligibility is restricted to 18-70 years old men or women who are using a highly
      effective birth control method or are not of childbearing potential;subjects with not treated
      by statins in six months before signature of the informed consent.Subjects with diabetes, a
      history of myocardial infarction or other clinical evidence of atherosclerotic vascular
      disease or treated are not eligible for participation in the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2015</start_date>
  <completion_date type="Anticipated">May 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change of LDL-C</measure>
    <time_frame>12 weeks ( including 2,4,8,18,24,38,52 weeks)</time_frame>
    <description>Percent change from baseline in LDL-C after 12 treatment among the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change of non-HDL-C</measure>
    <time_frame>12 weeks ( including 2,4,8,18,24,38,52 weeks)</time_frame>
    <description>Percent change from baseline in non-HDL-C after 12 treatment among the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of HDL-C</measure>
    <time_frame>12 weeks ( including 2,4,8,18,24,38,52 weeks)</time_frame>
    <description>Percent change from baseline in HDL-C after 12 treatment among the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of TC, TG, Apo B, Apo Al</measure>
    <time_frame>2,4,8,12,18,24,38,52 weeks</time_frame>
    <description>Percent change from baseline in TC, TG, Apo B, Apo Al after treatment among the groups</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>HS-25 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-25 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-25 20mg, Placebo of Aorvastatin 1 tablet, oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-25 10mg combination with Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-25 20mg combination with Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-25 20mg, Aorvastatin 10mg, oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of HS-25 and Aorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-25 10mg</intervention_name>
    <description>HS-25 10mg add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet</description>
    <arm_group_label>HS-25 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-25 10mg combination with Atorvastatin</intervention_name>
    <description>HS-25 10mg, Atorvastatin 10mg, Placebo of Atorvastatin HS-25 1 tablet</description>
    <arm_group_label>HS-25 10mg combination with Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-25 20mg combination with Atorvastatin</intervention_name>
    <description>HS-25 20mg, Atorvastatin 10mg</description>
    <arm_group_label>HS-25 20mg combination with Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 10mg</description>
    <arm_group_label>HS-25 10mg combination with Atorvastatin</arm_group_label>
    <arm_group_label>HS-25 20mg combination with Atorvastatin</arm_group_label>
    <arm_group_label>Aorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-25 20mg</intervention_name>
    <arm_group_label>HS-25 20mg</arm_group_label>
    <other_name>HS-25 20mg, placebo of Atorvastatin 1 tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebe of HS-25 and Atorvastatin</intervention_name>
    <description>Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets</description>
    <arm_group_label>HS-25 10mg</arm_group_label>
    <arm_group_label>HS-25 20mg</arm_group_label>
    <arm_group_label>HS-25 10mg combination with Atorvastatin</arm_group_label>
    <arm_group_label>Aorvastatin</arm_group_label>
    <arm_group_label>Placebo of HS-25 and Aorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are 18 to 70 years of age, male or female using a highly effective birth
             control method or not of child-bearing potential, at Visit 1 (screening visit);

          -  LDL-C 3.36mmol/L (130 mg/dL) to 4.88 mmol/L (189 mg/dL) (inclusive) on a cholesterol
             lowering diet but no lipid modifying drug treatment (statins) for at least 6 weeks
             before signed written informed consent;

          -  A qualifying LDL-C value must be obtained at the beginning and end of the placebo
             run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the value at
             Visit 2, higher or lower; the average of both qualifying values must be in the range
             of 3.36mmol/L (130 mg/dL) to 4.88 mmol/L (189 mg/dL) (inclusive) for inclusion in the
             study.

        Exclusion Criteria:

          -  Liver transaminases &gt; 1.5 x upper limit of normal.

          -  Homozygous Familial Hypercholesterolemia.

          -  Subject who was diagnosed as diabetes with aged greater than 40 years old.

          -  Subject who was diagnosed as diabetes with one of the following of cardiovascular risk
             factorss: Hypertention Bp ≥ 140/90mmHg,or smoking, or low HDL-C (1.04mmol/L), or
             BMI≥28kg/m2.

          -  Women who are pregnant or breast feeding.

          -  Atherosclerotic cardiovascular disease including Arteriosclerotic heart disease, Acute
             coronary syndrome，Coronary artery bypass graft,Coronary angioplastyPeripheral
             arteriosclerosis,Cerebrovascular accident - history of Severe Endiocrine disease (for
             example Thyroid function abnormal) - History of a positive test for human
             immunodeficiency virus, hepatitis B or hepatitis C.

          -  History of advanced cancer - Arrhythmias need to be treated by medications

          -  Had severe injured or surgery in 6 months before study start.

          -  Hypersensitive to HS-25 or place.

          -  History of intolerance to ezetimibe.

          -  Participation other studies in three months.

          -  Treatment with a fibric acid derivative (eg, fenofibrate, gemfibrozil), probucol,
             warfarin, systemic corticosteroid, cyclosporine or other immunosuppressant agent
             within the prior 12 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianan Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

